Bulls view BODI stock positively due to its recent stock option repricing at $6.43, which could enhance employee retention and morale, potentially driving long-term growth. Despite underperforming the market in 2024, analysts like Roth MKM have set a strong buy rating with a price target of $12, implying significant upside. However, mixed earnings performance and declining revenues remain challenges for sustained bullish momentum.